Premium
ESTIMATION OF LONG‐TERM SURVIVAL WITH POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB FOR PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA (R/R DLBCL)
Author(s) -
Sehn L.H.,
Flowers C.,
McMillan A.,
Morschhauser F.,
Salles G.,
Felizzi F.,
Laun A.,
Qayum N.,
Thuresson P.O.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.66_2630
Subject(s) - bendamustine , medicine , rituximab , oncology , survival analysis , lymphoma , surgery